{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T05:57:53Z","timestamp":1771912673219,"version":"3.50.1"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Behavioural Brain Research"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.bbr.2016.06.017","type":"journal-article","created":{"date-parts":[[2016,6,14]],"date-time":"2016-06-14T07:57:40Z","timestamp":1465891060000},"page":"138-147","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Selective corticotropin-releasing factor 1 receptor antagonist E2508 has potent antidepressant-like and anxiolytic-like properties in rodent models"],"prefix":"10.1016","volume":"312","author":[{"given":"Ryota","family":"Taguchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kodo","family":"Shikata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiaki","family":"Furuya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuhiro","family":"Ino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kogyoku","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisashi","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbr.2016.06.017_bib0005","doi-asserted-by":"crossref","first-page":"6517","DOI":"10.1073\/pnas.78.10.6517","article-title":"Primary structure of corticotropin-releasing factor from ovine hypothalamus","volume":"78","author":"Spiess","year":"1981","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbr.2016.06.017_bib0010","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1126\/science.6267699","article-title":"Characterization of 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin","volume":"213","author":"Vale","year":"1981","journal-title":"Science"},{"key":"10.1016\/j.bbr.2016.06.017_bib0015","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1124\/pr.55.1.3","article-title":"International union of pharmacology. XXXVI. Current status of the nomenclature for receptors for corticotropin-releasing factor and their ligands","volume":"55","author":"Hauger","year":"2003","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.bbr.2016.06.017_bib0020","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2174\/187152706777950684","article-title":"Corticotropin releasing factor (CRF) receptor signaling in the central nervous system: new molecular targets","volume":"5","author":"Hauger","year":"2006","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"10.1016\/j.bbr.2016.06.017_bib0025","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1210\/endo.133.6.8243338","article-title":"Cloning and functional expression of a rat brain corticotropin releasing factor (CRF) receptor","volume":"133","author":"Perrin","year":"1993","journal-title":"Endocrinology"},{"key":"10.1016\/j.bbr.2016.06.017_bib0030","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/1096-9861(20001211)428:2<191::AID-CNE1>3.0.CO;2-U","article-title":"Distribution of mRNAs encoding CRF receptors in brain and pituitary of rat and mouse","volume":"428","author":"Van Pett","year":"2000","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.bbr.2016.06.017_bib0035","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1210\/er.2005-0034","article-title":"The molecular mechanisms underlying the regulation of the biological activity of corticotropin-releasing hormone receptors: implications for physiology and pathophysiology","volume":"27","author":"Hillhouse","year":"2006","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.bbr.2016.06.017_bib0040","first-page":"281","article-title":"Plasma dexamethasone concentrations and differential suppression response of cortisol and corticosterone in depressives and controls","volume":"19","author":"Holsboer","year":"1984","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.bbr.2016.06.017_bib0045","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1176\/ajp.143.7.896","article-title":"The corticotropin-releasing hormone stimulation test in patients with panic disorder","volume":"143","author":"Roy-Byrne","year":"1986","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.bbr.2016.06.017_bib0050","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1159\/000126778","article-title":"Increased numbers of corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus of depressed patients","volume":"60","author":"Raadsheer","year":"1994","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.bbr.2016.06.017_bib0055","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1176\/ajp.152.9.1372","article-title":"Corticotropin-releasing hormone mRNA levels in the paraventricular nucleus of patients with Alzheimer\u2019s disease and depression","volume":"152","author":"Raadsheer","year":"1995","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.bbr.2016.06.017_bib0060","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1021\/jm070578k","article-title":"Synthesis and SAR of 2-aryloxy-4-alkoxy-pyridines as potent orally active corticotropin releasing factor 1 receptor antagonists","volume":"51","author":"Chen","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbr.2016.06.017_bib0065","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.drudis.2010.02.011","article-title":"Progress in corticotropin-releasing factor-1 antagonist development","volume":"15","author":"Zorrilla","year":"2010","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.bbr.2016.06.017_bib0070","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1517\/13543784.2011.565330","article-title":"Corticotropin releasing factor antagonists for major depressive disorder","volume":"20","author":"Paez-Pereda","year":"2011","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.bbr.2016.06.017_bib0075","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0022-3956(00)00016-9","article-title":"Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated","volume":"34","author":"Zobel","year":"2000","journal-title":"J. Psychiatry Res."},{"key":"10.1016\/j.bbr.2016.06.017_bib0080","doi-asserted-by":"crossref","first-page":"5255","DOI":"10.1021\/jm300259r","article-title":"Synthesis and structure-activity relationships of pyrazolo[1,5-a]pyridine derivatives: potent and orally active antagonists of corticotropin-releasing factor 1 receptor","volume":"55","author":"Takahashi","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbr.2016.06.017_bib0085","article-title":"Discovery of E2508, a novel orally active antagonist of corticotropin-releasing factor 1 (CRF1) receptor","author":"Ino","year":"2012","journal-title":"Abstr. Soc. Neurosci."},{"key":"10.1016\/j.bbr.2016.06.017_bib0090","article-title":"E2508, a novel orally active antagonist of corticotropin-releasing factor 1 (CRF1) receptor, has potent anxiolytic-like and antidepressant-like properties in rodent models","author":"Taguchi","year":"2012","journal-title":"Abstr. Soc. Neurosci."},{"key":"10.1016\/j.bbr.2016.06.017_bib0095","first-page":"327","article-title":"Behavioural despair in mice: a primary screening test for antidepressants","volume":"229","author":"Porsolt","year":"1977","journal-title":"Arch. Int. Pharmacodyn. Ther."},{"key":"10.1016\/j.bbr.2016.06.017_bib0100","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1037\/1064-1297.5.2.107","article-title":"Acute and chronic antidepressant drug treatment in the rat forced swimming test model of depression","volume":"5","author":"Detke","year":"1997","journal-title":"Exp. Clin. Psychopharmacol."},{"key":"10.1016\/j.bbr.2016.06.017_bib0105","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/0091-3057(81)90219-7","article-title":"Conditioned defensive burying: a new paradigm for the study of anxiolytic agents","volume":"15","author":"Treit","year":"1981","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.bbr.2016.06.017_bib0110","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s002130051018","article-title":"Chronic fluoxetine inhibits sexual behavior in the male rat: reversal with oxytocin","volume":"144","author":"Cantor","year":"1999","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.bbr.2016.06.017_bib0115","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1046\/j.1471-4159.1995.64010394.x","article-title":"Coupling of corticotropin-releasing hormone receptors to adenyl cyclase in human Y-79 retinoblastoma cells","volume":"64","author":"Olianas","year":"1995","journal-title":"J. Neurochem"},{"key":"10.1016\/j.bbr.2016.06.017_bib0120","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1210\/endo-110-1-272","article-title":"In vitro corticotropin-releasing factor-induced secretion of adrenocorticotropin, \u03b2-endorphine, and corticosterone","volume":"110","author":"Rivier","year":"1982","journal-title":"Endocrinology"},{"key":"10.1016\/j.bbr.2016.06.017_bib0125","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1126\/science.6101294","article-title":"Receptors for the age of anxiety: pharmacology of the benzodiazepines","volume":"207","author":"Tallman","year":"1980","journal-title":"Science"},{"key":"10.1016\/j.bbr.2016.06.017_bib0130","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/266730a0","article-title":"Depression: a new animal model sensitive to antidepressant treatments","volume":"266","author":"Porsolt","year":"1977","journal-title":"Nature"},{"key":"10.1016\/j.bbr.2016.06.017_bib0135","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ejphar.2004.07.091","article-title":"Antidepressant-like activity of corticotropin-releasing factor type-1 receptor antagonists in mice","volume":"499","author":"Nielsen","year":"2004","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bbr.2016.06.017_bib0140","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.pbb.2006.12.021","article-title":"Comparison of the V1b antagonist SSR149415, and the CRF1 antagonist, CP-154,526, in rodent models of anxiety and depression","volume":"86","author":"Hodgson","year":"2007","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.bbr.2016.06.017_bib0145","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00213-005-2164-z","article-title":"The effects of CRF antagonists, antalarmin, CP154,526, LWH234, and R121919 in the forced swim test and on swim-induced increases in adrenocorticotropin in rats","volume":"180","author":"Jutkiewicz","year":"2005","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.bbr.2016.06.017_bib0150","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1054\/npep.2001.0851","article-title":"The effects of CRA 1000 a non-peptide antagonist of corticotropin-releasing factor receptor type 1, on adaptive behavior in the rat","volume":"35","author":"Harro","year":"2001","journal-title":"Neuropeptides"},{"key":"10.1016\/j.bbr.2016.06.017_bib0155","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1124\/jpet.301.1.333","volume":"301","author":"Griebel","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bbr.2016.06.017_bib0160","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ejphar.2003.11.032","article-title":"Anxiolytic- and antidepressant-like profile of a new CRF1 receptor antagonist, R278995\/CRA0450","volume":"485","author":"Chaki","year":"2004","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bbr.2016.06.017_bib0165","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0893-133X(02)00299-3","article-title":"Brain penetrance, receptor occupancy and antistress in vivo efficacy of a small molecule corticotropin releasing factor type I receptor selective antagonist","volume":"27","author":"Heinrichs","year":"2002","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bbr.2016.06.017_bib0170","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/00004714-199902000-00013","article-title":"Effects of SSRIs on sexual function: a critical review","volume":"19","author":"Rosen","year":"1999","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.bbr.2016.06.017_bib0175","first-page":"25","article-title":"Fluoxetine-induced sexual dysfunction","volume":"51","author":"Herman","year":"1990","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.bbr.2016.06.017_bib0180","first-page":"66","article-title":"The role of serotonin in sexual dysfunction: fluoxetine-associated orgasm dysfunction","volume":"52","author":"Zajecka","year":"1991","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.bbr.2016.06.017_bib0185","first-page":"119","article-title":"Fluoxetine-induced sexual dysfunction and an open trial of yohimbine","volume":"53","author":"Jacobsen","year":"1992","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.bbr.2016.06.017_bib0190","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0009-9236(97)90198-3","article-title":"Comparative sexual side effects of bupropion fluoxetine, paroxetine, and sertraline","volume":"61","author":"Modell","year":"1997","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.bbr.2016.06.017_bib0195","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2190\/1DHU-Y7L7-9GKG-V7WV","article-title":"Male sexual side effects associated with antidepressants: a descriptive clinical study of 32 patients","volume":"25","author":"Hsu","year":"1995","journal-title":"Int. J. Psychiatry Med."},{"key":"10.1016\/j.bbr.2016.06.017_bib0200","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0091-3057(98)00010-0","article-title":"The selective serotonin reuptake inhibitor fluoxetine reduces sexual motivation in male rats","volume":"60","author":"Matuszcyk","year":"1998","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.bbr.2016.06.017_bib0205","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0022-3956(03)00076-1","article-title":"Treatment with the CRH1-receptor-antagonist R121919 improves sleep-EEG in patients with depression","volume":"38","author":"Held","year":"2004","journal-title":"J. Psychiatry Res."},{"key":"10.1016\/j.bbr.2016.06.017_bib0210","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S0022-3956(03)00070-0","article-title":"Treatment of depression with the CRH-1-receptor antagonist R121919: endocrine changes and side effects","volume":"37","author":"Kunzel","year":"2003","journal-title":"J. Psychiatry Res."},{"key":"10.1016\/j.bbr.2016.06.017_bib0215","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1176\/appi.ajp.2008.07071199","article-title":"A 6-week randomized placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depression","volume":"165","author":"Binneman","year":"2008","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.bbr.2016.06.017_bib0220","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/da.20695","article-title":"Multicenter randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder","volume":"27","author":"Coric","year":"2010","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.bbr.2016.06.017_bib0225","doi-asserted-by":"crossref","first-page":"G1299","DOI":"10.1152\/ajpgi.00011.2009","article-title":"Do corticotropin releasing factor-1 receptors influence colonic transit and bowel function in women with irritable bowel syndrome?","volume":"296","author":"Sweetser","year":"2009","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.bbr.2016.06.017_bib0230","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.pharmthera.2010.08.011","article-title":"Therapeutic utility of non-peptidic CRF1 receptor antagonists in anxiety, depression and stress-related disorders: evidence from animal models","volume":"128","author":"Kehne","year":"2010","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bbr.2016.06.017_bib0235","series-title":"Diagnostic and Statistical Manual of Mental Disorders: DSM-5","author":"American Psychiatric Association","year":"2013"},{"key":"10.1016\/j.bbr.2016.06.017_bib0240","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1126\/science.6334362","article-title":"Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients","volume":"226","author":"Nemeroff","year":"1984","journal-title":"Science"}],"container-title":["Behavioural Brain Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166432816303710?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166432816303710?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T07:20:20Z","timestamp":1536650420000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166432816303710"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":48,"alternative-id":["S0166432816303710"],"URL":"https:\/\/doi.org\/10.1016\/j.bbr.2016.06.017","relation":{},"ISSN":["0166-4328"],"issn-type":[{"value":"0166-4328","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Selective corticotropin-releasing factor 1 receptor antagonist E2508 has potent antidepressant-like and anxiolytic-like properties in rodent models","name":"articletitle","label":"Article Title"},{"value":"Behavioural Brain Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbr.2016.06.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}